RenovoRx, (id:5943 RNXT)
1.29 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 11:54:32 PM)
Exchange closed, opens in 9 hours 35 minutes
-0.77 USD (-0.77%)
9.32 USD (9.32%)
30.30 USD (30.30%)
5.74 USD (5.74%)
89.71 USD (89.71%)
-84.36 USD (-84.36%)
About RenovoRx,
Market Capitalization 30.96M
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
| Headquarters (address) |
4546 El Camino Real Los Altos 94022 CA United States |
| Phone | 650 284 4433 |
| Website | https://renovorx.com |
| Employees | 8 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | RNXT |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 0.531 - 2.35 |
| Market Capitalization | 30.96M |
| P/E trailing | -1.30 |
| P/E forward | -3.15 |
| Price/Book | 4.55 |
| Beta | 0.993 |
| EPS | -0.580 |
| EPS United States (ID:6, base:3404) | 24.21 |